by A Yale researcher poised to start a crucial clinical trial received an ominous email from a pharmaceutical company. “There is undoubtedly a financial motivation,” he said—and there could be millions on the line. A look into how the system works.In New Haven, meanwhile, Dr. Joseph Vinetz, an infectious disease doctor at Yale School of Medicine, is seeking to launch a clinical study of the drug camostat mesylate, a generic medication approved in Japan to treat chronic pancreatitis that he hopes can be approved and marketed to treat COVID-19. If the trial succeeds, he said, this could be ”a total game changer.” But the process is proving fraught. Within hours of registering his trial on a National Institutes of Health website on April 20, he received an email from a large U.S.
Topics:
Mike Norman considers the following as important:
This could be interesting, too:
Bill Haskell writes Promoting the General Welfare, The Supreme Court’s Version of Doing So
NewDealdemocrat writes For the second time in three months, the Household jobs Survey was recessionary
Angry Bear writes Medicare Payment Advisory Commission report to Congress Brief
Angry Bear writes Western “Values”
A Yale researcher poised to start a crucial clinical trial received an ominous email from a pharmaceutical company. “There is undoubtedly a financial motivation,” he said—and there could be millions on the line.
A look into how the system works.
In New Haven, meanwhile, Dr. Joseph Vinetz, an infectious disease doctor at Yale School of Medicine, is seeking to launch a clinical study of the drug camostat mesylate, a generic medication approved in Japan to treat chronic pancreatitis that he hopes can be approved and marketed to treat COVID-19. If the trial succeeds, he said, this could be ”a total game changer.” But the process is proving fraught. Within hours of registering his trial on a National Institutes of Health website on April 20, he received an email from a large U.S. pharmaceutical company. “They are trying to take my project and engulf it for their proprietary [financial] gain,” Vinetz told me. “I take that email as a threat.”
“I Take That as a Threat”: Big Pharma Is Meddling in the Race for a COVID-19 Treatment